NFKB1 and cancer: Admittedly, our data provide several lines of evidence that NF-κB-signaling is impaired in DC-tumor fusion cells, but, even though NF-κB-inhibitors are starting to emerge in the clinic, it would obviously not make sense to administer NF-κB-agonists to cancer patients.